- Home
- XPEL vs ATTO Comparison
XPEL vs ATTO Comparison
Compare XPEL & ATTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XPEL | ATTO |
|---|---|---|
| Founded | 1999 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | 2019 | 2026 |
Fundamental Metrics
Financial Performance| Metric | XPEL | ATTO |
|---|---|---|
| Price | $38.07 | $15.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $57.00 | $42.20 |
| AVG Volume (30 Days) | 251.8K | ★ 324.6K |
| Earning Date | 11-04-2026 | 09-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.12 | N/A |
| EPS | ★ 1.62 | N/A |
| Revenue | ★ $476,200,000.00 | N/A |
| Revenue This Year | $11.71 | N/A |
| Revenue Next Year | $10.64 | N/A |
| P/E Ratio | $23.75 | ★ N/A |
| Revenue Growth | ★ 13.27 | N/A |
| 52 Week Low | $36.99 | $12.94 |
| 52 Week High | $55.91 | $28.00 |
Technical Indicators
Market Signals| Indicator | XPEL | ATTO |
|---|---|---|
| Relative Strength Index (RSI) | 28.90 | 51.32 |
| Support Level | $36.99 | $12.94 |
| Resistance Level | $46.97 | $16.83 |
| Average True Range (ATR) | 2.12 | 1.32 |
| MACD | -0.56 | 0.33 |
| Stochastic Oscillator | 0.28 | 73.64 |
Price Performance
Historical ComparisonAbout XPEL XPEL Inc.
XPEL Inc is a supplier of protective films, coatings, and related services principally to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from Product, which includes Paint protection film and Window film. The company derives revenue from Service, which includes Software, Cutbank credits, and Installation labor. The majority of revenue is derived from the United States.
About ATTO Attovia Therapeutics Inc. Common Stock
Attovia Therapeutics Inc is a clinical stage biotechnology company focused on research and development of therapeutic products in the fields of immune-mediated diseases. Its product pipeline includes ATTO-1310 and ATTO-2306 for immune-dermatology indications and ATTO-1091 for inflammatory diseases, including inflammatory bowel disease (IBD). The company's product candidates are developed using its ATTOBODY biologics platform.